<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459916</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 Antibody Seroprevalence in Gabon: Findings from a Nationwide Household Serosurvey in a Sub-Saharan Africa Country.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1582</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101582</ELocationID><Abstract><AbstractText>Seroconversion surveys of anti-SARS-CoV-2 antibodies provide accurate estimates of the prevalence of SARS-CoV-2 infections. This nationwide population-based cross-sectional serosurvey aimed to evaluate the prevalence of SARS-CoV-2 antibodies among residents in Gabon and compare the estimated cumulative number of COVID-19 cases with the officially registered number of laboratory-confirmed cases up to December 2021. Households in each province were randomly selected. Twenty-eight localities, including sixteen urban and twelve rural, were randomly selected for the study. Whole blood samples were collected in dry tubes from all study participants nationwide within 15 days. Serum samples were used to measure SARS-CoV-2-specific ELISA titers. Overall, data from 1672 households were analyzed. Out of the 3659 participants, 3175 were found to be positive for SARS-CoV-2 antibodies, resulting in a crude seroprevalence of 86.77%. Stratification of study participants by age group showed the highest seroprevalences in the 20-29 and 40-49 age groups with 91.78% (95% CI: 89.5-93.6) and 91.42% (95% CI: 88.7-93.5), respectively. Nyanga province had the lowest prevalence (72.8%), and Estuaire and Ogooué-Lolo provinces had the highest prevalence (90 and 92%). Our results suggest a high transmission rate in the Gabonese population 21 months after the first SARS-CoV-2 case in the country. This high seroprevalence estimate could indicate that the population may not have adequately implemented or appropriately adhered to the applied infection control measures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zoa-Assoumou</LastName><ForeName>Samira</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2714-1781</Identifier><AffiliationInfo><Affiliation>Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire Professeur Daniel Gahouma (LPDG), Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Essone-Ndong</LastName><ForeName>Paulin</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné BP 118, Gabon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire Nationale de Santé Publique (LNSP), Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamou</LastName><ForeName>Rafiou</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné BP 118, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyegue-Liabagui</LastName><ForeName>Sandrine Lydie</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Unité d'Evolution, Epidémiologie et Résistance Parasitaire, Centre Interdisciplinaire de Recherches Médicales de Franceville (CIRMF), Franceville BP 769, Gabon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Biologie, Faculté des Sciences, Université des Sciences et Techniques de Masuku (USTM), Franceville BP 942, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mveang Nzoghe</LastName><ForeName>Amandine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU-Mère-Enfant Fondation Jeanne Ebori, Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roméo Adegbite</LastName><ForeName>Bayodé</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné BP 118, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintsa Ndong</LastName><ForeName>Armel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire Nationale de Santé Publique (LNSP), Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mboyis-Kandem</LastName><ForeName>Herve</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magossou Mbadinga</LastName><ForeName>Marien Juliet Verraldy</ForeName><Initials>MJV</Initials><AffiliationInfo><Affiliation>Unité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU-Mère-Enfant Fondation Jeanne Ebori, Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ndjoyi-Mbiguino</LastName><ForeName>Angelique</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amalet Akagha</LastName><ForeName>Armel Brice</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Organisation Mondiale de la Santé, Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngou-Milama</LastName><ForeName>Krystina Mengue Me</ForeName><Initials>KMM</Initials><AffiliationInfo><Affiliation>Organisation Mondiale de la Santé, Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagayoko</LastName><ForeName>Magaran Monzon</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Organisation Mondiale de la Santé, Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aboubacar</LastName><ForeName>Inoua</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Organisation Mondiale de la Santé, Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lekana-Douki</LastName><ForeName>Jean-Bernard</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-9417-1358</Identifier><AffiliationInfo><Affiliation>Unité d'Evolution, Epidémiologie et Résistance Parasitaire, Centre Interdisciplinaire de Recherches Médicales de Franceville (CIRMF), Franceville BP 769, Gabon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Parasitologie-Mycologie Médecine Tropicale, Faculté de Médecine, Université des Sciences de la Santé (USS), Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djoba Siawaya</LastName><ForeName>Joel Fleury</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Unité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU-Mère-Enfant Fondation Jeanne Ebori, Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adegnika</LastName><ForeName>Ayola Akim</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné BP 118, Gabon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut für Tropenmedizin, Universität Tübingen, German Center for Infection Research (DZIF), 72074 Tübingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Parasitology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngoungou</LastName><ForeName>Edgard-Brice</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Epidemiology-Biostatistics and Medical Informatics (DEBIM), Faculty of Medicine, University of Health Sciences, Libreville BP 4009, Gabon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Covid-Gabonese Group</LastName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Unity Studies</GrantID><Agency>WHO</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005681" MajorTopicYN="N" Type="Geographic">Gabon</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005191" MajorTopicYN="N">Family Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Gabon</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">population-based survey</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459916</ArticleId><ArticleId IdType="pmc">PMC11512409</ArticleId><ArticleId IdType="doi">10.3390/v16101582</ArticleId><ArticleId IdType="pii">v16101582</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rodriguez-Morales A.J., Cardona-Ospina J.A., Gutiérrez-Ocampo E., Villamizar-Peña R., Holguin-Rivera Y., Escalera-Antezana J.P., Alvarado-Arnez L.E., Bonilla-Aldana D.K., Franco-Paredes C., Henao-Martinez A.F., et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel. Med. Infect. Dis. 2020;34:101623. doi: 10.1016/j.tmaid.2020.101623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101623</ArticleId><ArticleId IdType="pmc">PMC7102608</ArticleId><ArticleId IdType="pubmed">32179124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoa-Assoumou S., Ndeboko B., Manouana G.P., Houechenou R.M.A., Bikangui R., Mveang-Nzoghe A., Ondo G.N., Mbongo-Kama E., Lell B., Abe H., et al. SARS-CoV-2 emerging variants in Africa: View from Gabon. Lancet Microbe. 2021;2:e349. doi: 10.1016/S2666-5247(21)00125-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00125-7</ArticleId><ArticleId IdType="pmc">PMC8186850</ArticleId><ArticleId IdType="pubmed">34124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Iroungou B.A., Mangouka L.G., Bivigou-Mboumba B., Moussavou-Boundzanga P., Obame-Nkoghe J., Nzigou Boucka F., Mouinga-Ondeme A., Aghokeng A.F., Tchoua R., Pineau P., et al. Demographic and Clinical Characteristics Associated with Severity, Clinical Outcomes, and Mortality of COVID-19 Infection in Gabon. JAMA Netw. Open. 2021;4:e2124190. doi: 10.1001/jamanetworkopen.2021.24190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.24190</ArticleId><ArticleId IdType="pmc">PMC8441589</ArticleId><ArticleId IdType="pubmed">34519768</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . Coordinated Global Research Roadmap: 2019 Novel Coronavirus. World Health Organization; Geneva, Switzerland: 2020.  [(accessed on 14 May 2022)].  Available online:  https://www.who.int/docs/default-source/coronaviruse/coordinated-global-research-roadmap.pdf?sfvrsn=21b0f5c4_1&amp;download=true.</Citation></Reference><Reference><Citation> [(accessed on 17 June 2024)].  Available online:  https://www.unicef.org/gabon/communiqu%C3%A9s-de-presse/le-gabon-recoit-100-620-doses-de-vaccin-pfizer-expediees-le-covax#:~:text=L'arriv%C3%A9e%20du%20vaccin%20Pfizer,repose%20sur%20le%20vaccin%20Sinopharm.</Citation></Reference><Reference><Citation>Bergeri I., Lewis H.C., Subissi L., Nardone A., Valenciano M., Cheng B., Glonti K., Williams B., Omolade Abejirinde I.-O., Simniceanu A., et al. Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza Other Respir. Viruses. 2022;16:7–13. doi: 10.1111/irv.12915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12915</ArticleId><ArticleId IdType="pmc">PMC8652791</ArticleId><ArticleId IdType="pubmed">34611986</ArticleId></ArticleIdList></Reference><Reference><Citation>Murhekar M.V., Bhatnagar T., Selvaraju S., Saravanakumar V., Vivian Thangaraj J.W., Shah N., Kumar M.S., Rade K., Sabarinathan R., Asthana S., et al. SARS-CoV-2 antibody seroprevalence in India, August-September 2020: Findings from the second nationwide household serosurvey. Lancet Glob. Health. 2021;9:e257–e266. doi: 10.1016/S2214-109X(20)30544-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30544-1</ArticleId><ArticleId IdType="pmc">PMC7906675</ArticleId><ArticleId IdType="pubmed">33515512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagara I., Woodford J., Kone M., Assadou M.H., Katile A., Attaher O., Zeguime A., Doucoure M., Higbee E., Lane J., et al. Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study. Clin. Infect. Dis. 2022;74:1030–1038. doi: 10.1093/cid/ciab589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab589</ArticleId><ArticleId IdType="pmc">PMC8394825</ArticleId><ArticleId IdType="pubmed">34185847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleynhans J., Tempia S., Wolter N., von Gottberg A., Bhiman J.N., Buys A., Moyes J., McMorrow M.L., Kahn K., Gómez-Olivé F.X., et al. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021. Emerg. Infect. Dis. 2021;27:3020–3029. doi: 10.3201/eid2712.211465.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2712.211465</ArticleId><ArticleId IdType="pmc">PMC8632160</ArticleId><ArticleId IdType="pubmed">34477548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mveang Nzoghe A., Leboueny M., Kuissi Kamgaing E., Maloupazoa Siawaya A.C., Bongho E.C., Mvoundza Ndjindji O., Padzys G.-S., Ndeboko B., Ategbo S., Djoba Siawaya J.F. Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: Herd immunity, not there yet! BMC Res. Notes. 2021;14:152. doi: 10.1186/s13104-021-05570-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-021-05570-3</ArticleId><ArticleId IdType="pmc">PMC8056361</ArticleId><ArticleId IdType="pubmed">33879229</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami A., Sepidarkish M., Fazlzadeh A., Mokdad A.H., Sattarnezhad A., Esfandyari S., Riahi S.M., Mollalo A., Dooki M.E., Bayani M., et al. Update on SARS-CoV-2 seroprevalence: Regional and worldwide. Clin. Microbiol. Infect. 2021;27:1762–1771. doi: 10.1016/j.cmi.2021.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.09.019</ArticleId><ArticleId IdType="pmc">PMC8548624</ArticleId><ArticleId IdType="pubmed">34582980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbow M., Lell B., Jochems S.P., Cisse B., Mboup S., Dewals B.G., Jaye A., Dieye A. COVID-19 in Africa: Dampening the storm? Science. 2020;369:624–626. doi: 10.1126/science.abd3902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3902</ArticleId><ArticleId IdType="pubmed">32764055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wamai R.G., Hirsch J.L., Van Damme W., Alnwick D., Bailey R.C., Hodgins S., Alam U., Anyona M. What Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation of the SARS-CoV-2 Virus? Int. J. Environ. Res. Public Health. 2021;18:8638. doi: 10.3390/ijerph18168638.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18168638</ArticleId><ArticleId IdType="pmc">PMC8391172</ArticleId><ArticleId IdType="pubmed">34444386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyawale H.A., Moremi N., Mohamed M., Njwalila J., Silago V., Krone M., Konje E.T., Mirambo M.M., Mshana S.E. High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey. Int. J. Environ. Res. Public Health. 2022;19:11664. doi: 10.3390/ijerph191811664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191811664</ArticleId><ArticleId IdType="pmc">PMC9517516</ArticleId><ArticleId IdType="pubmed">36141938</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarju S., Wenlock R.D., Danso M., Jobe D., Jagne Y.J., Darboe A., Kumado M., Jallow Y., Touray M., Ceesay E.A., et al. High SARS-CoV-2 incidence and asymptomatic fraction during Delta and Omicron BA.1 waves in The Gambia. Nat. Commun. 2024;15:3814. doi: 10.1038/s41467-024-48098-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48098-3</ArticleId><ArticleId IdType="pmc">PMC11076623</ArticleId><ArticleId IdType="pubmed">38714680</ArticleId></ArticleIdList></Reference><Reference><Citation>Njenga M.K., Dawa J., Nanyingi M., Gachohi J., Ngere I., Letko M., Otieno C.F., Gunn B.M., Osoro E. Why is There Low Morbidity and Mortality of COVID-19 in Africa? Am. J. Trop. Med. Hyg. 2020;103:564–569. doi: 10.4269/ajtmh.20-0474.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0474</ArticleId><ArticleId IdType="pmc">PMC7410455</ArticleId><ArticleId IdType="pubmed">32484156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngere I., Dawa J., Hunsperger E., Otieno N., Masika M., Amoth P., Makayotto L., Nasimiyu C., Gunn B.M., Nyawanda B., et al. High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya. Int. J. Infect. Dis. 2021;112:25–34. doi: 10.1016/j.ijid.2021.08.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.08.062</ArticleId><ArticleId IdType="pmc">PMC8411609</ArticleId><ArticleId IdType="pubmed">34481966</ArticleId></ArticleIdList></Reference><Reference><Citation>Poustchi H., Darvishian M., Mohammadi Z., Shayanrad A., Delavari A., Bahadorimonfared A., Eslami S., Javanmard S.H., Shakiba E., Somi M.H., et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: A population-based cross-sectional study. Lancet Infect. Dis. 2021;21:473–481. doi: 10.1016/S1473-3099(20)30858-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30858-6</ArticleId><ArticleId IdType="pmc">PMC7833828</ArticleId><ArticleId IdType="pubmed">33338441</ArticleId></ArticleIdList></Reference><Reference><Citation>Nwosu K., Fokam J., Wanda F., Mama L., Orel E., Ray N., Meke J., Tassegning A., Takou D., Mimbe E., et al. SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon. Nat. Commun. 2021;12:5851. doi: 10.1038/s41467-021-25946-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25946-0</ArticleId><ArticleId IdType="pmc">PMC8494753</ArticleId><ArticleId IdType="pubmed">34615863</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>